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Purpose: The incidence of pain induced withdrawal
movement following intravenous injection of rocuronium is
high. This randomized, double-blind, placebo-controlled study
was designed to evaluate the effect of pretreatment of
remifentanil on the withdrawal movements due to intravenous
injection of rocuronium during anesthetic induction. Materials
and Methods: Ninety adult female patients undergoing
thyroidectomy were randomly allocated to three groups. Each
patient intravenously received one of three solutions of equal
volume (4 mL): normal saline (Group I, n = 30), 0.5 g/kg μ
remifentanil (Group II, n = 30) or 1 g/kg remifentanil (Group μ
III, n = 30). Thirty seconds after remifentanil administration,
anesthesia was induced with 5 mg/kg IV thiopental. Twenty
seconds after thiopental injection, 0.6 mg/kg IV rocuronium
was administered (injection rate of 0.5 mL/sec) and patients’
withdrawal movements were assessed. Mean arterial pressure
(MAP) and heart rate were assessed on arrival in the operation
room, before the tracheal intubation and immediately, 1 and
2 min after the tracheal intubation. Results: The incidence of
withdrawal movements was significantly lower in both of the
remifentanil groups (3 and 0% in Group II and III, respec-
tively) than in the saline group (70%). Remifentanil attenuated
the increase of heart rate and MAP immediately and 1 min
after the tracheal intubation. Conclusion: The pretreatment
with 0.5 and 1.0 g/kg remifentanil of bolus doses prevented μ
the withdrawal movements caused by rocuronium injection,
and effectively blunted cardiovascular activation following
tracheal intubation.
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INTRODUCTION
Generally, injection pain of rocuronium is
reported to occur in 50 - 80% of patients.
1 Most
patients complain of severe burning pain in their
arms even with only a subparalyzing dose for the
prevention of fasciculation or accelerating muscle
relaxation for endotracheal intubation. Even after
loss of consciousness during induction of an-
esthesia, intravenous rocuronium can still elicit
withdrawal movements such as withdrawal of the
injected hand and arm or a generalized movement
of the body.
2 These withdrawal movements may
cause dislocation or displacement of the IV catheter,
causing difficulty in administrating additional
drugs and subsequent risk of cardiovascular
activation.
3
Numerous methods have been suggested to
attenuate these withdrawal movements which are
related to rocuronium-induced pain,
4-11 nevertheless,
a dramatic, available and convenient way with a
satisfactory low failure rate and without side
effects has still not been found.
Remifentanil is a synthetic and esterase-meta-
bolized opioid with a rapid onset, an ultra-short
duration of action and a stable, short context-
sensitive half-time compared with other opioids.
12,13
Therefore, hemodynamic alterations by this drug,
such as decrease of blood pressure and heart rate,
can be expected to last shorter than by alfentanil,
sufentanil, or fentanyl. These characteristics have
recently made remifentanil an ideal coping drug
against noxious stimuli.
This randomized, double-blind, placebo-con-
trolled study was designed to determine whether
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remifentanil could prevent or attenuate the
rocuronium-induced withdrawal movements
when treated prior to rocuronium injection at
bolus doses used commonly in clinical practice. In
addition, the effects of pretreated remifentanil on
cardiovascular responses following laryngoscopy
and endotracheal intubation were investigated.
MATERIALS AND METHODS
After obtaining the approval from the institu-
tional review board and the written informed
consents from patients, 90 female patients, aged
between 19 and 65 years and ASA physical status
I or II, undergoing elective thyroidectomy were
enrolled in this study. Patients with hypertension,
ischemic heart diseases, severe bradycardia (heart
rate < 45 beats/min), chronic pain syndrome and
neuromuscular disorders were excluded. Patients
who had received analgesics or sedatives within
the previous 24 hours were also excluded from
the study.
On the day of the operation, a 20 gauge
intravenous cannula was inserted at the distal
part of the forearm cephalic vein of each patient.
Thirty minutes prior to induction of anesthesia,
0.004 mg/kg glycopyrrolate was given intraven-
ously to each patient. Patients were monitored
with noninvasive arterial pressure (NIBP), pulse
oximetry and electrocardiogram throughout their
stay in the operating room. In addition, to
evaluate the effect of remifentanil on the onset
time of rocuronium, acceleromyography (TOF-
Watch, Organon , Netherland) electrodes were
placed on the ulnar nerve area of the wrist. And
the acceleration transducer was taped to the volar
aspect of the thumb at the interpharyngeal joint
to measure the developed tension of the adductor
pollicis muscle.
Patients were randomly allocated into 3 groups
using a sealed envelope method to receive one of
three solutions of equal volume (4 mL) intraven-
ously: normal saline (Group I, n = 30), 0.5 g/kg μ
remifentanil (Group II, n = 30) or 1 g/kg remi μ -
fentanil (Group III, n = 30). The administered
volume of the remifentanil (Ultiva, GlaxoSmith-
Kline , UK) solution was adjusted to 4 mL by
mixing normal saline before it was administered
to the patients of Group II and III. The syringe
containing the study drug was prepared by an
independent researcher. Patients, anesthesia pro-
viders and investigators who evaluated the
withdrawal movements were blinded to the
treatment group. In each group, 4 mL of normal
saline or the same volume of solution containing
different doses of remifentanil was administered
over 30 sec. Thirty sec after the administration of
the study drug, anesthesia was induced with
2.5% 5 mg/kg thiopental which was injected at
the rate of 0.5 mL/sec. Immediately after the
administration of thiopental, mask ventilation was
started with 5 L/min flow O2. Twenty sec after
the administration of thiopental when the patient
was unconscious and the eyelash reflex was
abolished, 1% rocuronium (0.6mg/kg) without
dilution was injected over 5 sec. During the
injection of rocuronium, the movements of
hands, arms or shoulders were observed by
another anesthesiologist who was blinded to the
regimen of the pretreated drug. To estimate the
incidence of withdrawal response, a 4 point
grading system which has been utilized in
several previous studies was employed as shown
in Table 1, in which the patient’s response to the
injection of rocuronium was classified
accordingly.
Then, anesthesia was maintained with 3.0 vol %
Table 1. Grading of Withdrawal Response
Degree of movement Patient’s response
0 No response or withdrawal
1 Movement at the wrist only
2 Movement/withdrawal involving arm only
3 Generalized response-withdrawal or movement in more than one extremity, cough, or
breath holdingRemifentanil and Rocuronium-Induced Pain
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sevoflurane in 100% O2 until the end of the study.
The acceleromyography was calibrated automa-
tically to set up supramaximal stimuli (60 mA for
the ulnar nerve), defined as the current 20% above
the threshold for maximal response and the value
of the control twitch height was assessed through
continuous 1 Hz-single twitch monitoring. In this
study, the onset time of rocuronium was defined
as the time lag from the end of rocuronium
injection to the maximal depression (below 5%) of
the single twitch. The onset time of rocuronium in
each Group was measured and compared. Twenty
seconds after the single twitch value fell below
5%, endotracheal intubation was performed. Mask
ventilation and intubation was performed by the
same anesthesiologist.
Mean arterial pressure (MAP) and heart rate
were assessed on arrival in the operation room,
before the tracheal intubation, and immediately, 1
and 2 min after the tracheal intubation.
The side effects after remifentanil injection such
as bradycardia (more than 20% decrease of baseline
heart rate), chest tightness, muscle rigidity,
desaturation (SpO2 < 90%), and the frequency of
coughing were also evaluated. And local signs
such as redness, erythema and venous sequelae
on the forearm where rocuronium was injected
were also checked at the end of the injection as
well as immediately and 12 hrs after emergence
from anesthesia.
Statistical analyses were performed using SPSS
version 12.5 (SPSS Inc., Chicago, IL, USA). To
detect a 40% difference in the incidence of with-
drawal movement on rocuronium injection at a
significant level of 5% and a power of 90%, 30
patients per group were required. Data are
presented as mean ± SD or number of patients.
Patients' characteristics such as age, height, weight,
hemodynamic parameters and the onset time of
rocuronium were compared with one-way
ANOVA with Bonferroni’s correction. For the
comparison of withdrawal responses, the Kruskal-
Wallis test was used. Regarding the comparison of
the frequency of coughing between Groups II and
III, the Fisher exact test was used. The results
were considered statistically significant when a p
value < 0.05.
RESULTS
The groups' demographic data did not signifi-
cantly differ (Table 2).
Group II and Group III showed a significant
reduction in withdrawal movements compared to
Group I (p = 0.000 by Kruskal-Wallis test). There
were no significant differences in the degree of
withdrawal movements between Group II and III
Table 2. Demographic Data
Group I Group II Group III
Age (yrs) 42.8 ± 10.3 43.9 ± 11.2 42.8 ± 11.4
Weight (kg) 57.3 ± 8.1 57.7 ± 5.9 55.2 ± 6.8
Height (cm) 159.6 ± 5.7 159.9 ± 6.1 158.2 ± 5.8
Onset time (sec) 59.1 ± 16.6 61.3 ± 13.7 56.9 ± 10.5
All values are mean ± SD.
Onset time, the onset time of rocuronium.
Table 3. Withdrawal Response Scores in Three Groups
Group Withdrawal response scores
0 1 2 3
I 9 (30) 12 (40) 4 (13) 5 (17)
II 29 (97) 1 (3) 0 (0) 0 (0)
III 30 (100) 0 (0) 0 (0) 0 (0)
Data are number of patients (%).Byung In Choi, et al.
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(p = 0.326) (Table 3).
Groups II and III showed statistically significant
blunting effect on increase of heart rate and MAP
during anesthetic induction compared with Group
I (Figs. 1 and 2). Both 0.5 and 1.0 g/kg remi μ -
fentanil attenuated the increase of heart rate and
MAP, especially immediately and 1 min after
endotracheal intubation. There were no statistical
differences in these cardiovascular blunting effects
between Group II and III. As for the heart rate,
the blunting effect in Group II and III persisted
until 1 min after intubation and was diminished
by 2 min after intubation (Fig. 1). No severe
bradycardia was found in Group II and III. On the
other hand, the blunting effect on the MAP of
remifentanil was significant in both Group II and
III until 1 min after intubation, but this effect
persisted until 2 min after intubation only in
Group III (Fig. 2).
Regarding the side effects after remifentanil
injection, the only main side effect observed was
coughing, although two cases of chest tightness,
one in Group II and one in Group III, were
observed. Groups II and III showed cough attacks
in 3 and 8 cases, respectively. Group II showed a
lesser frequency of cough attacks than Group III.
Meanwhile, no patient in group I showed cough
development. Furthermore, no redness, erythema
or venous sequelae was observed in any of
patients up to 12 hrs after emergence from anes-
thesia.
The onset time of rocuronium was not affected
by the dosages of remifentanil (Table 2).
DISCUSSION
In this study, we found that pretreatment with
remifentanil (both 0.5 and 1.0 g/kg) of bolus μ
doses dramatically prevented the withdrawal
movements caused by rocuronium injection, and
effectively blunted the cardiovascular activation
following laryngoscopy and endotracheal intuba-
tion.
Since rocuronium can induce muscle relaxation
within 1 min when a bolus of large amount is
used (more than 0.9 mg/kg), it can be an attrac-
tive alternative to succinylcholine. However, the
withdrawal response due to the injection pain
may make rocuronium the choice next to succinyl-
choline in rapid sequence intubation.
14
Thus, numerous methods have been suggested
to attenuate these withdrawal movements related
to rocuronium induced pain; pretreatments with
lidocaine,
4 ondansetron,
5,6 metoclopramide,
7 sodium
bicarbonate,
8 magnesium sulphate,
8 fentanyl,
5
ketamine,
9 or alfentanil
8 prior to an injection of
rocuronium, an injection of a mixture of
rocuronium and sodium bicarbonate
10,11 or a
mixture of rocuronium and lidocaine. However,
these pretreatment methods are rather limited in
Fig. 1. Changes in heart rate during anesthetic induction.
Base: before induction, Pre-intu: just before endotracheal
intubation, imm.postintu: immediately after endotracheal
intubation, postintu. 1 min: 1 min after endotracheal
intubation, postintu 2 min: 2 min after endotracheal
intubation. *p = 0.012, p = 0.985, p = 0.007
§p = 0.043, p =
0.945,
¶p = 0.039.
Fig. 2. Changes in mean arterial pressure (MAP) during
anesthetic induction. Base: before induction, Pre-intu: just
before endotracheal intubation, imm.postintu: immedi-
ately after endotracheal intubation, postintu. 1 min: 1 min
after endotracheal intubation, postintu 2 min: 2 min after
endotracheal intubation. *p = 0.000, p = 0.987, p = 0.000,
§p
= 0.036, p = 0.617,
¶p = 0.002, **p = 0.008.Remifentanil and Rocuronium-Induced Pain
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effectiveness and not always convenient because
those often require the use of tourniquet. The
method using a mixture of rocuroniun and
lidocaine has not shown definite side effects, but
was found to be minimally effective in reducing
the injection pain of rocuronium. And a mixture
of rocuronium and sodium bicarbonate can form
carbon dioxide bubbles. Although previous
studies showed that the pretreatment administra-
tion of fentanyl was also a simple and efficient way
to attenuate the injection pain of rocuronium
15
and pretreatment of alfentanil also effectively
attenuated the injection pain of propofol,
16
fentanyl has a relatively long duration of action
compared with remifentanil, and the fact that
plasma clearance and elimination of alfentanil are
reduced in patients with liver failure make us
hesitate to use this drug in patients with
decreased hepatic function.
17 Meanwhile, there is
no accumulation of remifentanil even in patients
with severe renal or hepatic dysfunction.
18
In this study, even a bolus dose of 0.5 g/kg of μ
remifentanil prior to rocuronium injection nearly
completely reduced the withdrawal response.
Thus, it is concluded that even a half dose of
remifentanil 1 g/kg, which is the com μ monly
recommended bolus dose of remifentanil 1 - 2
min prior to intubation, is effective in preventing
the withdrawal responses caused by injection pain
of rocuronium. These results are very encouraging
compared to other previous results because the
method is convenient and has a low failure rate.
In this study, remifentanil was not only applied
to reduce the withdrawal responses, but also to
attenuate hemodynamic changes following endo-
tracheal intubation. Hemodynamic effects by
remifentanil, such as decreases of blood pressure
and heart rate, can be expected to last shorter than
by alfentanil, sufentanil, or fentanyl. According to
Hall et al., in induction of anesthesia with
propofol, rocuronium and 1% isoflurane, a bolus
dose of 0.5 g/kg of remifentanil followed by an μ
infusion rate of 0.25 g/kg/min effectively blunted μ
the sympathetic activation following endotracheal
intubation.
19 In the present study, the bolus
injection of remifentanil was not followed by
infusion; instead, 1.5 MAC of sevoflurane was
combined. According to our data, a bolus dose of
0.5 and 1.0 g/kg of remifentanil showed similarly μ
effective results in attenuating the hemodynamic
change following endotracheal intubation.
This study demonstrated that the onset time of
rocuronium was not affected by the dosage of
remifentanil. Though 3.0 vol % sevoflurane was
used for anesthetic induction in this study and the
potentiating effect of sevoflurane on rocuronium-
induced neuromuscular block is widely known, it
is unlikely that combination of sevoflurane with
remifentanil has an advantage over remifentanil
alone in hastening an onset time of muscle
relaxation.
In the present study, marked side effects of
remifentanil such as bradycardia, chest tightness,
muscle rigidity and desaturation were not found.
The only important side effect observed was
coughing. Groups II and III showed 3 and 8 cases
of cough attacks (more than two times of coughing
after injection of remifentanil), respectively. Group
II showed a lesser frequency of cough attacks than
Group III. Based on our results, the reduction of
frequency of coughing upon the injection of
remifentanil can be achieved by the selection of an
optimal dosage of remifentanil.
In the present study, patients in 19 - 65 years of
age were enrolled, therefore, pediatric patients
were excluded. In pediatric patients, a withdrawal
incidence of 83% to 84% was observed after
injection of rocuronium, and an incidence of
generalized movement of 48 - 49% was reported,
compared to only 14% in adult patients.
20 Also,
while only 13% male patients demonstrated with-
drawal responses, 30% of female patients demon-
strated withdrawal movements.
21 Moreover, 22%
of females had severe reactions compared to only
5% of males.
21 Recruitment of only female subjects,
excluding pediatric subjects, substantially con-
tributed to obtain a homogenous cohort in this
study, leaving a further investigation about whether
the promising conclusion drawn from female
subjects holds true either in pediatric cohort
behind.
In selecting study subjects, we excluded
patients with extremely old and young ages, and
severe bradycardia (< 45 beats/min). In these
patients, remifentanil may give rise to harmful
effects such as abrupt bradycardia or hypotension.
Based on the results of this study, a smaller dose
of remifentanil, i.e. a dose of 0.5 g/kg of remi μ -Byung In Choi, et al.
Yonsei Med J Vol. 49, No. 2, 2008
fentanil, may be recommended to elderly patients
and patients with bradycardia, because a lower
dosage also exhibits similar effect in preventing
the withdrawal responses and attenuating cardio-
vascular activation.
In conclusion, we demonstrated that pretreat-
ment with remifentanil in both 0.5 and 1.0 g/kg μ
of bolus doses dramatically prevented the with-
drawal movements caused by rocuronium injection,
and effectively attenuated cardiovascular activation
following laryngoscopy and endotracheal intuba-
tion.
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